Moderna shares surged approximately 55% over the past 30 days, driven by a unanimous FDA advisory committee vote backing its mRNA-based seasonal flu vaccine and a transformative Science Day presentation. The FDA's Vaccines and Related Biological Products Advisory Committee voted 9-0 that the benefits of mFLUSIVA (mRNA-1010) outweigh its risks for adults aged 50 and older, with a final regulatory decision expected by August 5, 2026.

Reported Q2 2026 operating revenue of $49.8 billion, up 0.8% year over year. Diluted EPS reached $6.71 and adjusted diluted EPS hit $7.45, exceeding internal outlook.

PNC reported second quarter 2026 net income of $2.1 billion and diluted EPS of $4.81, or $4.85 as adjusted. Revenue reached a record $6.88 billion, up 21% from the prior year.

BNY reported record total revenue of $5.7 billion for the second quarter of 2026, up 13% year-over-year. Diluted earnings per share reached $2.45, a 27% increase from the prior year.

BlackRock reported Q2 2026 revenue of $7.08 billion, up 31% year-over-year. Adjusted diluted EPS reached $13.91, beating consensus estimates and rising 15% from the prior year.

Morgan Stanley reported record net revenues of $21.3 billion for the second quarter ended June 30, 2026. Diluted earnings per share reached $3.46, up from $2.13 in the same quarter a year earlier.

Johnson & Johnson reported second-quarter 2026 sales of $25.3 billion, up 6.6% year over year on a reported basis. Adjusted earnings per share reached $2.90, exceeding the consensus estimate of $2.85.

SNDK plunged -14.33% during regular trading Wednesday, falling from a prior close of $1,757.82 to approximately $1,505.94 intraday, as a broad memory chip rout intensified. The sell-off was triggered by contagion from SK Hynix shares tumbling ~15% in South Korea following its record Nasdaq debut, dragging the entire memory sector lower.

Micron shares plunged -9.50% during regular trading Wednesday, dropping from a prior close of $983.12 to approximately $889.68 intraday, as a broad semiconductor selloff swept through the memory sector. The selloff was triggered by renewed concerns over memory chip pricing and looming oversupply after SK Hynix's Nasdaq listing, where it raised $26.5 billion to fund plans to double DRAM production by 2030.

Apogee Therapeutics (APGE) surged approximately 55% over the last 30 days, driven primarily by the announcement of a definitive acquisition agreement with AbbVie at $135.11 per share in cash. The all-cash deal values Apogee at roughly $10.9 billion and represents a substantial premium over where shares traded before the announcement.

ENRD shares plunged approximately -13.82% during Wednesday's regular session, tumbling from a previous close of $6.15 to an intraday low near $5.30, hitting a new all-time low. The selloff continues the cascade triggered by the July 8 SEC Form F-1 filing, which registered up to 103.96 million ADSs for resale by existing securityholders — representing roughly 51.2% of total outstanding shares.

ENRD shares are down approximately -11.38% during the regular session, falling from a prior close of $6.15 to $5.45 intraday, extending a sustained post-SPAC downtrend. The primary overhang is the F-1 registration statement filed July 8 with the SEC, registering up to 103.96 million ADSs for resale by existing securityholders — roughly 51% of total shares outstanding.

BOT dropped -10.81% during regular trading on July 15, falling to ~$32.74 after surging +13.23% to $36.71 the prior session. The decline follows the announcement that RoboStrategy completed ~$16M in private share issuances at a weighted average price of ~$35.50 per share, below yesterday's close, triggering dilution concerns.

DELL plunged -11.97% during regular morning trading, hitting a session low of $397.69 — its largest intraday drop since April 2025 — as a confluence of sector-wide AI fears and company-specific pressures triggered a sharp selloff. The primary catalyst: reports that Meta is planning to lease surplus AI training and inference capacity raised fears that hyperscalers may have over-built, threatening future AI server orders for system integrators like Dell.

Dell Technologies shares have surged over 230% year-to-date in 2026, propelled by explosive AI-optimized server demand and record quarterly results reported in late May. The company booked $24.4 billion in AI orders in its fiscal first quarter and exited with a $51.3 billion AI backlog, reinforcing its position as a leading AI infrastructure provider.

Kymera Therapeutics shares surged approximately 32% over the past 30 days, climbing from around $85.59 on June 15 to $113.24 as of mid-July 2026. The rally was ignited by the early completion of enrollment in the Phase 2b BROADEN2 trial of lead candidate KT-621 for atopic dermatitis, nearly six months ahead of schedule.

Cytokinetics (CYTK) surged approximately 14.5% over the last 30 days, climbing from $71.38 on June 15, 2026, to $81.70 as of mid-July 2026, driven by mounting commercial momentum for Myqorzo and bullish analyst calls. Over the broader quarter, the stock gained roughly 25%, reflecting the company's successful transition into a commercial-stage biotech following the U.S. launch of its first FDA-approved drug, Myqorzo (aficamten).

Silicon Motion Technology (SIMO) shares gained approximately 9.2% over the last 30 days, supported by surging AI-driven enterprise storage demand and a series of dramatic analyst price target increases. Morgan Stanley raised its SIMO price target from $155 to $400 in early July, while Wedbush lifted its target to $400 and Bank of America set a Street-high $450, all citing the accelerating NAND cycle tied to AI data center buildouts.

Bio-Techne shares surged approximately 27% over the past 30 days, driven by Merck KGaA's announcement of an $11.3 billion all-cash acquisition at $73 per share. The acquisition offer, representing a 36% premium to Bio-Techne's one-month volume-weighted average trading price, immediately repriced the stock from the mid-$50s to above $70.

Molina Healthcare shares surged approximately 19.7% in the last 30 days, closing at $241.56 on July 14, 2026, up from $201.87 on June 15, 2026. The rally was fueled by a major Illinois Medicaid contract win, multiple analyst price-target increases, and an index reclassification into the Russell 2500 Value Index.